{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:21:33Z","timestamp":1781187693215,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jsat.2019.05.015","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T11:17:47Z","timestamp":1559301467000},"page":"15-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective"],"prefix":"10.1016","volume":"104","author":[{"given":"Suzanne","family":"Kinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia R.","family":"Houck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Mayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Loveland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Daley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jsat.2019.05.015_bb0005","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1360-0443.2009.02539.x","article-title":"Comparison of costs and utilization among buprenorphine and methadone patients","volume":"104","author":"Barnett","year":"2009","journal-title":"Addiction"},{"issue":"Suppl. 8","key":"10.1016\/j.jsat.2019.05.015_bb0010","first-page":"S235","article-title":"Cost and utilization outcomes of opioid-dependence treatments","volume":"17","author":"Baser","year":"2011","journal-title":"American Journal of Managed Care"},{"key":"10.1016\/j.jsat.2019.05.015_bb0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ypmed.2018.01.019","article-title":"Use of a prescription opioid registry to examine opioid misuse and overdose in an integrated health system","volume":"110","author":"Campbell","year":"2018","journal-title":"Prevention Medicine"},{"key":"10.1016\/j.jsat.2019.05.015_bb0020","series-title":"Medication-assisted treatment models of care for opioid use disorder in primary care settings (vol. AHRQ publication no. 16(17)-EHC039-EF)","author":"Chou","year":"2016"},{"issue":"8","key":"10.1016\/j.jsat.2019.05.015_bb0025","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1377\/hlthaff.2010.0532","article-title":"The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine","volume":"30","author":"Clark","year":"2011","journal-title":"Health Affairs (Millwood)"},{"key":"10.1016\/j.jsat.2019.05.015_bb0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jsat.2015.05.001","article-title":"Risk factors for relapse and higher costs among Medicaid members with opioid dependence or abuse: Opioid agonists, comorbidities, and treatment history","volume":"57","author":"Clark","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.05.015_bb0035","series-title":"Analysis of drug-related overdose deaths in Pennsylvania, 2016","author":"DEA","year":"2017"},{"key":"10.1016\/j.jsat.2019.05.015_bb0040","series-title":"The opioid threat in Pennsylvania","author":"DEA","year":"2018"},{"key":"10.1016\/j.jsat.2019.05.015_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.07.035","article-title":"Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: Implications for clinical use and policy","volume":"144","author":"Greenwald","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2019.05.015_bb0050","series-title":"Drug overdose deaths in the United States, 1999\u20132017. NCHS data brief no. 329 NCHS Data Brief No. 329","author":"Hedegaard","year":"2018"},{"issue":"1","key":"10.1016\/j.jsat.2019.05.015_bb0055","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.05.015_bb0060","author":"Indivior UK Ltd"},{"issue":"10","key":"10.1016\/j.jsat.2019.05.015_bb0065","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2215-0366(15)00366-1","article-title":"Mortality risk of opioid substitution therapy with methadone versus buprenorphine: A retrospective cohort study","volume":"2","author":"Kimber","year":"2015","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.jsat.2019.05.015_bb0070","first-page":"IV26","article-title":"Assessing comorbidity using claims data: An overview","author":"Klabunde","year":"2002","journal-title":"Medical Care"},{"issue":"5","key":"10.1016\/j.jsat.2019.05.015_bb0075","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/add.13270","article-title":"Association between trajectories of buprenorphine treatment and emergency department and inpatient utilization","volume":"111","author":"Lo Ciganic","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.05.015_bb0080","doi-asserted-by":"crossref","DOI":"10.1186\/1940-0640-9-16","article-title":"Costs of care for persons with opioid dependence in commercial integrated health systems","volume":"9","author":"Lynch","year":"2014","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1016\/j.jsat.2019.05.015_bb0085","article-title":"Effects of medication-assisted treatment on mortality among opioids users: A systematic review and meta-analysis","author":"Ma","year":"2018","journal-title":"Molecular Psychiatry"},{"issue":"2","key":"10.1016\/j.jsat.2019.05.015_bb0090","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.drugalcdep.2013.07.018","article-title":"Economic evaluation: A comparison of methadone versus buprenorphine for opiate substitution treatment","volume":"133","author":"Maas","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1016\/j.jsat.2019.05.015_bb0095","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/ajad.12553","article-title":"Three year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration","volume":"26","author":"Manhapra","year":"2017","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.jsat.2019.05.015_bb0100","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database Systematic Review"},{"issue":"3","key":"10.1016\/j.jsat.2019.05.015_bb0105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.drugalcdep.2010.04.018","article-title":"Methadone maintenance and the cost and utilization of health care among individuals dependent on opioids in a commercial health plan","volume":"111","author":"McCarty","year":"2010","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"10.1016\/j.jsat.2019.05.015_bb0110","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11414-017-9553-z","article-title":"Treating opioid dependence with buprenorphine in the safety net: Critical learning from clinical data","volume":"44","author":"Rieckmann","year":"2017","journal-title":"The Journal of Behavioral Health Services & Research"},{"key":"10.1016\/j.jsat.2019.05.015_bb0115","series-title":"SAS\/STAT\u00ae 13.2 user's guide","author":"SAS Institute Inc","year":"2014"},{"issue":"5","key":"10.1016\/j.jsat.2019.05.015_bb0120","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s11606-010-1609-1","article-title":"Healthy user and related biases in observational studies of preventive interventions: A primer for physicians","volume":"26","author":"Shrank","year":"2011","journal-title":"Journal of General Internal Medicine"},{"issue":"7","key":"10.1016\/j.jsat.2019.05.015_bb0125","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2105\/AJPH.93.7.1137","article-title":"Area deprivation and widening inequalities in US mortality, 1969\u20131998","volume":"93","author":"Singh","year":"2003","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.jsat.2019.05.015_bb0130","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jsat.2019.05.015_bb0135","series-title":"The determinations report: A report on the physician waiver program established by the drug addiction treatment act of 2000 (\u201cDATA\u201d)","author":"Substance Abuse and Mental Health Services Administration","year":"2006"},{"issue":"4","key":"10.1016\/j.jsat.2019.05.015_bb0140","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jsat.2013.10.014","article-title":"Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients","volume":"46","author":"Tkacz","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.jsat.2019.05.015_bb0145","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/fampra\/17.3.261","article-title":"The development of polypharmacy. A longitudinal study","volume":"17","author":"Veehof","year":"2000","journal-title":"Family Practice"},{"key":"10.1016\/j.jsat.2019.05.015_bb0150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","article-title":"Long-term retention in office based opioid treatment with buprenorphine","volume":"74","author":"Weinstein","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.jsat.2019.05.015_bb0155","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1468-0009.2006.00458.x","article-title":"The effect of substance abuse treatment on Medicaid expenditures among general assistance welfare clients in Washington state","volume":"84","author":"Wickizer","year":"2006","journal-title":"Milbank Quarterly"},{"key":"10.1016\/j.jsat.2019.05.015_bb0160","series-title":"The opioid epidemic and Medicaid's role in facilitating access to treatment issue brief","author":"Zur","year":"2018"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547218305488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547218305488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:49:24Z","timestamp":1760039364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547218305488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":32,"alternative-id":["S0740547218305488"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2019.05.015","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2019.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}